PUBLISHER: GlobalData | PRODUCT CODE: 1689004
PUBLISHER: GlobalData | PRODUCT CODE: 1689004
Prenatal Screening Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2036 is built to visualize quantitative and qualitative market trends within In Vitro Diagnostics therapeutic area.
Prenatal screening describes tests that detect potential problems that affect the viability and development of the fetus using both less invasive and more invasive sampling techniques. Prenatal Screening is now routinely used in developed countries for early detection of chromosomal abnormalities and NTDs.In most countries, maternal serum screening and ultrasound remain standard-of-care for screening of pregnant women for chromosome aneuploidies and other birth defects.
Each of the covered 39 countries color-coded and fully-sourced market models are equipped with epidemiology based indications. The interactive excel deliverable covers value, volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are -
Currently marketed Prenatal Screening and evolving competitive landscape -
Global, Regional and Country level market specific insights -
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: Illumina Inc, BGI Genomics Co Ltd, Novacyt UK Holdings Ltd, Eurofins Scientific SE, Agilent Technologies Inc, Roche Diagnostics International Ltd, Revvity Inc, Beckman Coulter Inc, Abbott Laboratories, Siemens Healthineers AG, Quidel Corp, Thermo Fisher Scientific Inc, Tosoh Corp, and Others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable